NCT04997980

Brief Summary

Investigators' aim is to assess whether the administration of amiodarone during resuscitation could cause a reduction of the values of the amplitude spectral area (AMSA). Amiodarone is recommended for the treatment of cardiac arrest due to ventricular tachycardia/ventricular fibrillation (VT/VF) ( with a low level of recommendation cause of conflicting results. AMSA is a parameter expressing the amplitude of VF and it has been shown to predict defibrillation success and the return of spontaneous circulation (ROSC). No data are available so far about the impact of amiodarone administration on AMSA values.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
629

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2015

Longer than P75 for all trials

Geographic Reach
3 countries

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
6.5 years until next milestone

First Submitted

Initial submission to the registry

July 18, 2021

Completed
23 days until next milestone

First Posted

Study publicly available on registry

August 10, 2021

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

March 8, 2024

Status Verified

March 1, 2024

Enrollment Period

9 years

First QC Date

July 18, 2021

Last Update Submit

March 7, 2024

Conditions

Keywords

AMSAamiodaroneOut-Of-Hospital Cardiac Arrest

Outcome Measures

Primary Outcomes (1)

  • AMSA values

    to determine whether AMSA values in the Amiodarone group are lower than in the NO Amiodarone gorup

    through study completion, an average of 1 year

Secondary Outcomes (5)

  • Successful defibrilaltion

    through study completion, an average of 1 year

  • ROSC

    through study completion, an average of 1 year

  • Survived event

    through study completion, an average of 1 year

  • Survival to hospital discharge

    through study completion, an average of 1 year

  • Prediction

    through study completion, an average of 1 year

Study Arms (2)

Amiodarone group

Patients who did receive amiodarone during the attempt of resuscitation

Drug: Amiodarone Injection

NO Amiodarone

Patients who did receive amiodarone during the attempt of resuscitation

Interventions

Amiodarone group

Eligibility Criteria

Age1 Year - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All the consecutive patients suffering of out-of-hospital cardiac arrest with a shockable presenting rhythm and receiving an advanced attempt of resuscitation.

You may qualify if:

  • clinical:
  • patients with out-of-hospital cardiac arrest
  • shockable presenting rhythm
  • resuscitation attempted
  • advanced resuscitation attempted
  • technical: - VF cardiac arrest (and not VT)

You may not qualify if:

  • clinical:
  • non-shockable presenting rhythm
  • resuscitation not attempted
  • technical:
  • \- AMSA not evaluable

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Fondazione IRCCS Policlinico San Matteo

Pavia, 27100, Italy

Location

Oslo University Hospital

Oslo, 0010, Norway

Location

Vestfold Hospital trust

Tønsberg, Norway

Location

BioRes Research Group

Bilbao, Spain

Location

Related Publications (28)

  • Schwartz PJ, Zaza A. The Sicilian Gambit revisited--theory and practice. Eur Heart J. 1992 Nov;13 Suppl F:23-9. doi: 10.1093/eurheartj/13.suppl_f.23. No abstract available.

    PMID: 1478220BACKGROUND
  • Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. J Am Coll Cardiol. 1984 Apr;3(4):1059-71. doi: 10.1016/s0735-1097(84)80367-8.

    PMID: 6368644BACKGROUND
  • Marinchak RA, Friehling TD, Kline RA, Stohler J, Kowey PR. Effect of antiarrhythmic drugs on defibrillation threshold: case report of an adverse effect of mexiletine and review of the literature. Pacing Clin Electrophysiol. 1988 Jan;11(1):7-12. doi: 10.1111/j.1540-8159.1988.tb03925.x.

    PMID: 2449675BACKGROUND
  • Zhou L, Chen BP, Kluger J, Fan C, Chow MS. Effects of amiodarone and its active metabolite desethylamiodarone on the ventricular defibrillation threshold. J Am Coll Cardiol. 1998 Jun;31(7):1672-8. doi: 10.1016/s0735-1097(98)00160-0.

    PMID: 9626850BACKGROUND
  • Hohnloser SH, Dorian P, Roberts R, Gent M, Israel CW, Fain E, Champagne J, Connolly SJ. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation. 2006 Jul 11;114(2):104-9. doi: 10.1161/CIRCULATIONAHA.106.618421. Epub 2006 Jul 3.

    PMID: 16818810BACKGROUND
  • Jung W, Manz M, Pizzulli L, Pfeiffer D, Luderitz B. Effects of chronic amiodarone therapy on defibrillation threshold. Am J Cardiol. 1992 Oct 15;70(11):1023-7. doi: 10.1016/0002-9149(92)90354-2.

    PMID: 1414899BACKGROUND
  • Fain ES, Lee JT, Winkle RA. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. Am Heart J. 1987 Jul;114(1 Pt 1):8-17. doi: 10.1016/0002-8703(87)90300-0.

    PMID: 3604876BACKGROUND
  • Soar J, Berg KM, Andersen LW, Bottiger BW, Cacciola S, Callaway CW, Couper K, Cronberg T, D'Arrigo S, Deakin CD, Donnino MW, Drennan IR, Granfeldt A, Hoedemaekers CWE, Holmberg MJ, Hsu CH, Kamps M, Musiol S, Nation KJ, Neumar RW, Nicholson T, O'Neil BJ, Otto Q, de Paiva EF, Parr MJA, Reynolds JC, Sandroni C, Scholefield BR, Skrifvars MB, Wang TL, Wetsch WA, Yeung J, Morley PT, Morrison LJ, Welsford M, Hazinski MF, Nolan JP; Adult Advanced Life Support Collaborators. Adult Advanced Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Resuscitation. 2020 Nov;156:A80-A119. doi: 10.1016/j.resuscitation.2020.09.012. Epub 2020 Oct 21.

    PMID: 33099419BACKGROUND
  • Sanfilippo F, Corredor C, Santonocito C, Panarello G, Arcadipane A, Ristagno G, Pellis T. Amiodarone or lidocaine for cardiac arrest: A systematic review and meta-analysis. Resuscitation. 2016 Oct;107:31-7. doi: 10.1016/j.resuscitation.2016.07.235. Epub 2016 Aug 3.

    PMID: 27496262BACKGROUND
  • Tagami T, Yasunaga H, Yokota H. Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation. Crit Care. 2017 Mar 21;21(1):59. doi: 10.1186/s13054-017-1639-8.

    PMID: 28320450BACKGROUND
  • Tagami T, Matsui H, Tanaka C, Kaneko J, Kuno M, Ishinokami S, Unemoto K, Fushimi K, Yasunaga H. Amiodarone Compared with Lidocaine for Out-Of-Hospital Cardiac Arrest with Refractory Ventricular Fibrillation on Hospital Arrival: a Nationwide Database Study. Cardiovasc Drugs Ther. 2016 Oct;30(5):485-491. doi: 10.1007/s10557-016-6689-7.

    PMID: 27618826BACKGROUND
  • Chowdhury A, Fernandes B, Melhuish TM, White LD. Antiarrhythmics in Cardiac Arrest: A Systematic Review and Meta-Analysis. Heart Lung Circ. 2018 Mar;27(3):280-290. doi: 10.1016/j.hlc.2017.07.004. Epub 2017 Aug 23.

    PMID: 28988724BACKGROUND
  • Zhao H, Fan K, Feng G. Amiodarone and/or lidocaine for cardiac arrest: A Bayesian network meta-analysis. Am J Emerg Med. 2020 Oct;38(10):2185-2193. doi: 10.1016/j.ajem.2020.06.074. Epub 2020 Jul 5.

    PMID: 33071078BACKGROUND
  • Ong ME, Pellis T, Link MS. The use of antiarrhythmic drugs for adult cardiac arrest: a systematic review. Resuscitation. 2011 Jun;82(6):665-70. doi: 10.1016/j.resuscitation.2011.02.033. Epub 2011 Mar 27.

    PMID: 21444143BACKGROUND
  • Kudenchuk PJ, Leroux BG, Daya M, Rea T, Vaillancourt C, Morrison LJ, Callaway CW, Christenson J, Ornato JP, Dunford JV, Wittwer L, Weisfeldt ML, Aufderheide TP, Vilke GM, Idris AH, Stiell IG, Colella MR, Kayea T, Egan D, Desvigne-Nickens P, Gray P, Gray R, Straight R, Dorian P; Resuscitation Outcomes Consortium Investigators. Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest: The ALPS Study (Amiodarone, Lidocaine, or Placebo). Circulation. 2017 Nov 28;136(22):2119-2131. doi: 10.1161/CIRCULATIONAHA.117.028624. Epub 2017 Sep 13.

    PMID: 28904070BACKGROUND
  • Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, Hallstrom AP, Murray WA, Olsufka M, Walsh T. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999 Sep 16;341(12):871-8. doi: 10.1056/NEJM199909163411203.

    PMID: 10486418BACKGROUND
  • Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002 Mar 21;346(12):884-90. doi: 10.1056/NEJMoa013029.

    PMID: 11907287BACKGROUND
  • Ristagno G, Li Y, Fumagalli F, Finzi A, Quan W. Amplitude spectrum area to guide resuscitation-a retrospective analysis during out-of-hospital cardiopulmonary resuscitation in 609 patients with ventricular fibrillation cardiac arrest. Resuscitation. 2013 Dec;84(12):1697-703. doi: 10.1016/j.resuscitation.2013.08.017. Epub 2013 Sep 1.

    PMID: 24005007BACKGROUND
  • Ristagno G, Mauri T, Cesana G, Li Y, Finzi A, Fumagalli F, Rossi G, Grieco N, Migliori M, Andreassi A, Latini R, Fornari C, Pesenti A; Azienda Regionale Emergenza Urgenza Research Group. Amplitude spectrum area to guide defibrillation: a validation on 1617 patients with ventricular fibrillation. Circulation. 2015 Feb 3;131(5):478-87. doi: 10.1161/CIRCULATIONAHA.114.010989. Epub 2014 Dec 2.

    PMID: 25466976BACKGROUND
  • Salcido DD, Schmicker RH, Kime N, Buick JE, Cheskes S, Grunau B, Zellner S, Zive D, Aufderheide TP, Koller AC, Herren H, Nuttall J, Sundermann ML, Menegazzi JJ; Resuscitation Outcomes Consortium Investigators. Effects of intra-resuscitation antiarrhythmic administration on rearrest occurrence and intra-resuscitation ECG characteristics in the ROC ALPS trial. Resuscitation. 2018 Aug;129:6-12. doi: 10.1016/j.resuscitation.2018.05.028. Epub 2018 May 24.

    PMID: 29803703BACKGROUND
  • Frigerio L, Baldi E, Aramendi E, Chicote B, Irusta U, Contri E, Palo A, Compagnoni S, Fracchia R, Iotti G, Oltrona Visconti L, Savastano S; Lombardia CARe Researchers. End-tidal carbon dioxide (ETCO2) and ventricular fibrillation amplitude spectral area (AMSA) for shock outcome prediction in out-of-hospital cardiac arrest. Are they two sides of the same coin? Resuscitation. 2021 Mar;160:142-149. doi: 10.1016/j.resuscitation.2020.10.032. Epub 2020 Nov 10.

    PMID: 33181229BACKGROUND
  • Ristagno G, Gullo A, Berlot G, Lucangelo U, Geheb E, Bisera J. Prediction of successful defibrillation in human victims of out-of-hospital cardiac arrest: a retrospective electrocardiographic analysis. Anaesth Intensive Care. 2008 Jan;36(1):46-50. doi: 10.1177/0310057X0803600108.

    PMID: 18326131BACKGROUND
  • Aiello S, Perez M, Cogan C, Baetiong A, Miller SA, Radhakrishnan J, Kaufman CL, Gazmuri RJ. Real-Time Ventricular Fibrillation Amplitude-Spectral Area Analysis to Guide Timing of Shock Delivery Improves Defibrillation Efficacy During Cardiopulmonary Resuscitation in Swine. J Am Heart Assoc. 2017 Nov 4;6(11):e006749. doi: 10.1161/JAHA.117.006749.

    PMID: 29102980BACKGROUND
  • Hulleman M, Salcido DD, Menegazzi JJ, Souverein PC, Tan HL, Blom MT, Koster RW. Predictive value of amplitude spectrum area of ventricular fibrillation waveform in patients with acute or previous myocardial infarction in out-of-hospital cardiac arrest. Resuscitation. 2017 Nov;120:125-131. doi: 10.1016/j.resuscitation.2017.08.219. Epub 2017 Aug 24.

    PMID: 28844935BACKGROUND
  • Ruggeri L, Semeraro F, Ristagno G. Amplitude spectrum area: The "clairvoyance" during resuscitation in the era of predictive medicine. Resuscitation. 2017 Nov;120:A5-A6. doi: 10.1016/j.resuscitation.2017.09.011. Epub 2017 Sep 18. No abstract available.

    PMID: 28928017BACKGROUND
  • Hulleman M, Salcido DD, Menegazzi JJ, Souverein PC, Tan HL, Blom MT, Koster RW. Ventricular fibrillation waveform characteristics in out-of-hospital cardiac arrest and cardiovascular medication use. Resuscitation. 2020 Jun;151:173-180. doi: 10.1016/j.resuscitation.2020.02.027. Epub 2020 Mar 10.

    PMID: 32169604BACKGROUND
  • Aramendi E, Elola A, Alonso E, Irusta U, Daya M, Russell JK, Hubner P, Sterz F. Feasibility of the capnogram to monitor ventilation rate during cardiopulmonary resuscitation. Resuscitation. 2017 Jan;110:162-168. doi: 10.1016/j.resuscitation.2016.08.033. Epub 2016 Sep 23.

    PMID: 27670357BACKGROUND
  • Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol. 1991 Nov;31(11):1061-9. doi: 10.1002/j.1552-4604.1991.tb03673.x.

    PMID: 1753010BACKGROUND

MeSH Terms

Conditions

Out-of-Hospital Cardiac Arrest

Interventions

Amiodarone

Condition Hierarchy (Ancestors)

Heart ArrestHeart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

BenzofuransHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

July 18, 2021

First Posted

August 10, 2021

Study Start

January 1, 2015

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

March 8, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Data could be shared under motivated request following a proposal.

Locations